Last reviewed · How we verify
cabotegravir, CAB
cabotegravir, CAB is a Integrase strand transfer inhibitor (INSTI) Small molecule drug developed by ViiV Healthcare. It is currently FDA-approved for HIV-1 infection in treatment-experienced adults (as part of combination antiretroviral therapy), HIV-1 prevention in at-risk adults (pre-exposure prophylaxis, PrEP). Also known as: cabotegravir, CAB.
Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human host cell DNA.
Cabotegravir is an antiretroviral medication used to treat HIV infections and prevent HIV infection through pre-exposure prophylaxis (PrEP). It is also being studied for its potential use in contraception.
At a glance
| Generic name | cabotegravir, CAB |
|---|---|
| Also known as | cabotegravir, CAB |
| Sponsor | ViiV Healthcare |
| Drug class | Integrase strand transfer inhibitor (INSTI) |
| Target | HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Cabotegravir binds to the active site of HIV integrase and inhibits the strand transfer step of viral integration. By blocking this critical step in the HIV replication cycle, the drug prevents establishment of persistent infection. It is used as a long-acting injectable formulation for HIV treatment and prevention.
Approved indications
- HIV-1 infection in treatment-experienced adults (as part of combination antiretroviral therapy)
- HIV-1 prevention in at-risk adults (pre-exposure prophylaxis, PrEP)
Common side effects
- Injection site reactions
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men (PHASE2, PHASE3)
- Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
- A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) (PHASE2)
- Antiviral Long Acting Drugs Landing in People Living With HIV (NA)
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
- A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 (PHASE3)
- Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cabotegravir, CAB CI brief — competitive landscape report
- cabotegravir, CAB updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI
Frequently asked questions about cabotegravir, CAB
What is cabotegravir, CAB?
How does cabotegravir, CAB work?
What is cabotegravir, CAB used for?
Who makes cabotegravir, CAB?
Is cabotegravir, CAB also known as anything else?
What drug class is cabotegravir, CAB in?
What development phase is cabotegravir, CAB in?
What are the side effects of cabotegravir, CAB?
What does cabotegravir, CAB target?
Related
- Drug class: All Integrase strand transfer inhibitor (INSTI) drugs
- Target: All drugs targeting HIV integrase
- Manufacturer: ViiV Healthcare — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for HIV-1 infection in treatment-experienced adults (as part of combination antiretroviral therapy)
- Indication: Drugs for HIV-1 prevention in at-risk adults (pre-exposure prophylaxis, PrEP)
- Also known as: cabotegravir, CAB
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing